Copenhagen, Denmark, 7 June2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.
NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...
New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026
NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.
Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...
JAKARTA, Indonesia, June 7, 2026 /PRNewswire/ -- Indonesian retail and logistics sectors are aggressively restructuring supply chains following a major report revealing an 18.9%...